3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
6
Fallopian Tube Neoplasms
4
Carcinoma, Ovarian Epithelial
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Platinum-resistant Ovarian Cancer
1
Ovarian Cancer Recurrent
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Adenoviridae Infections
1
Interventions
Cyclophosphamide
62
Rituximab
52
fludarabine
34
Prednisone
34
Doxorubicin
29
Vincristine
26
Biopsy
26
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Bendamustine Hydrochloride
19
pembrolizumab
17
Lenalidomide
17
obinutuzumab
14
fludarabine phosphate
14
Etoposide
14
venetoclax
13
Tacrolimus
11
Mycophenolic Acid
10
Melphalan
10
Dexamethasone
10
zanubrutinib
9
ibrutinib
9
acalabrutinib
9
Radiotherapy
9
Gemcitabine
9
Cytarabine
9
Busulfan
9
Whole-Body Irradiation
8
Mesna
8
Filgrastim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
1-dodecylpyridoxal
×
1 year
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled